Mylan Expands EpiPen Recall to Some Devices Distributed in U.S.
(Bloomberg) -- Mylan NV said it was expanding a recall of its EpiPen allergy injection to some lots of the device that have been distributed in the U.S., after defects were found that could keep the injectors from working in an emergency.
Mylcan called the defect “extremely rare,” and is recalling 13 lots of the pens. The company said it will replace pens from the recalled lots at no cost, and that people should keep the ones they have until they get their replacements.
“The recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution,” the drugmaker said in a statement Friday. EpiPen is licensed by Mylan, and the pens are manufactured by Meridian Medical Technologies, a unit of Pfizer Inc.
Nina Devlin, a Mylan spokeswoman, didn't immediately respond to a request for comment.
EpiPen is one of Mylan's biggest products, making up the backbone of its specialty drugs division. The company has faced criticism over the drug's cost. EpiPen's wholesale price has jumped six-fold since Mylan acquired its marketing rights in 2007 and it now lists for about $600 for a two-pack. Mylan also sells a generic version of EpiPen for $300.
The injection is used to counteract dangerous allergic reactions, such as those from bee stings or food allergies.
To contact the reporter on this story: Jared S. Hopkins in New York at jhopkins38@bloomberg.net.
To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, John Lauerman
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
